Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Regenxbio (RGNX) EBT (2016 - 2025)

Regenxbio has reported EBT over the past 12 years, most recently at -$67.2 million for Q4 2025.

  • Quarterly results put EBT at -$67.2 million for Q4 2025, down 31.01% from a year ago — trailing twelve months through Dec 2025 was -$194.0 million (up 14.66% YoY), and the annual figure for FY2025 was -$194.0 million, up 14.59%.
  • EBT for Q4 2025 was -$67.2 million at Regenxbio, down from -$62.0 million in the prior quarter.
  • Over the last five years, EBT for RGNX hit a ceiling of $307.4 million in Q4 2021 and a floor of -$76.8 million in Q1 2022.
  • Median EBT over the past 5 years was -$61.9 million (2023), compared with a mean of -$27.2 million.
  • Peak annual rise in EBT hit 369.63% in 2021, while the deepest fall reached 764.6% in 2021.
  • Regenxbio's EBT stood at $307.4 million in 2021, then decreased by 28.32% to $220.4 million in 2022, then tumbled by 128.58% to -$63.0 million in 2023, then increased by 18.58% to -$51.3 million in 2024, then tumbled by 31.01% to -$67.2 million in 2025.
  • The last three reported values for EBT were -$67.2 million (Q4 2025), -$62.0 million (Q3 2025), and -$70.9 million (Q2 2025) per Business Quant data.